T. Burke

Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs

T. MacDonald, S. Morant, J. Goldstein, 2003, Gut.

Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib.

J. Schwartz, N. Maniadakis, J. Goldstein, 2000, Rheumatology.

Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

T. Burke, G. Mcinnes, G. Carides, 2006, Journal of Human Hypertension.

OP0138 Relative gastrointestinal toxicity of cox-2 specific and traditional nsaids in a high-risk population from a health maintenance organisation

J. Schwartz, J. Goldstein, T. Burke, 2001 .

Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

J. Edelman, B. Dahlöf, J. Edelman, 2004, Journal of Human Hypertension.

Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac

J. Lefkowith, J. Goldstein, T. Burke, 2002, Alimentary pharmacology & therapeutics.

Adherence to proton pump inhibitors or H2‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs

J. Dieleman, M. Sturkenboom, T. Burke, 2003, Alimentary pharmacology & therapeutics.